Category Archives: Hormone Replacement Therapy

The presented market report on the global Hormone Replacement Therapy market published by Fact.MR is a comprehensive analysis of the leading parameters that are likely to determine the growth of the Hormone Replacement Therapy market in the forthcoming decade. Further, the study dives in deep to investigate the micro and macro-economic factors that are projected to influence the global scenario of the Hormone Replacement Therapy market during the forecast period (2019-2029).

The market study reveals that the Hormone Replacement Therapy market is expected to grow at a CAGR of ~XX% and reach a value of ~USXX by the end of 2029. The report examines the current trends, growth opportunities, restraints, and market drivers that are projected to influence the overall dynamics of the Hormone Replacement Therapy market in the assessment period. The market study predicts the course of the global Hormone Replacement Therapy market post the COVID-19 pandemic and offers resourceful insights to market players pertaining to their business continuity strategies and more.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=2224

Hormone Replacement Therapy Market Segmentation

The report bifurcates the Hormone Replacement Therapy market into multiple segments to provide a clear picture of the Hormone Replacement Therapy market at a granular level. The key segments covered in the report include region, product type, application, and more.

Competitive Landscape

The report on hormone replacement therapy market offers intelligence on key participants in the hormone replacement therapy market. The key companies involved in the formulation of hormone replacement therapy products are thoroughly assessed and profiled in the report. Various facets of competition including SWOT analysis, product portfolio analysis, drug developments and innovations, strategies and key financials are covered. Key companies profiled in the report include Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals, Mylan N.V and Pfizer Inc.

Major companies in the hormone replacement therapy market are concentrating on expanding their current product portfolio. New hormone replacement therapy formulations being the core focus, companies are carrying out trials and gain FDA approvals. For instance, Novartis AGs research and development department delivered 6 critical FDA breakthrough therapy designations and 16 submissions in 2017. In May 2017, Novartis AG announced U.S. FDAs approval for its hormone replacement therapy tablets for hormone receptor positive and metastatic breast cancer treatment in postmenopausal women.

In February 2018, Novo Nordisk A/S concluded main phase of REAL 1 the pivotal phase 3 trial along with somapacitan, a long-acting growth hormone to treat adults with growth hormone deficiency.

Teva Pharmaceuticals Industries Ltd. introduced Vagifem in 2017 for the treatment of atrophic vaginitis. In January 2018, the company launched Estrace cream to treat moderate and severe symptoms of vaginal and vulgar atrophy occurring due to menopause. Likewise, Mylan N.V expanded its US portfolio in the womens healthcare range with U.S. FDA approval for Estradiol Vaginal Cream to treat vaginal atrophy.

Private equity firms are focused on acquiring emerging participants that are involved in drug delivery systems in the hormone replacement therapy space. For instance, Riverside Company has acquired DoseLogix in a bid to provide innovative dosing dispensers for ensuring accurate dosing medications of hormone replacement therapy and other conditions.

Click to know more on competitive scenario in the hormone replacement therapy market to understand key strategies of market participants

Definition

Hormone replacement therapy, also referred to as menopausal hormone therapy, is used to treat various symptoms related to menopause among women. Hormone replacement therapy replaces hormones that are low in level as women near menopause. There are various types of hormone replacement therapy such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy.

About the Report

The report on hormone replacement therapy market provides incisive insights on all aspects influencing growth in demand for hormone replacement therapy worldwide. The report provides a thorough analysis on demand of hormone replacement therapy across key regions in the globe along with sales of various hormone replacement therapy products.

Key drivers, challenges, trends and opportunities shaping the growth of the hormone replacement therapy market are also covered in the hormone replacement therapy market report. The hormone replacement therapy market report provides historical data assessment on use of hormone replacement therapy, current hormone replacement therapy scenario and future demand of hormone replacement therapy. The forecast projections provided cover a timeline of 10 years (2018-2028).

Market Structure

The hormone replacement therapy market is segmented in detail to cover every angle of the hormone replacement therapy space. The hormone replacement therapy market has been segmented on the basis of product type, by dosage form, by indication, by distribution channel and by region.

Various hormone replacement therapy products such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy is covered. By dosage form, hormone replacement therapy market is segmented into tablets, patches, injections, implants and creams. By indications, hormone replacement therapy market is categorized into menopause, osteoporosis, thyroid and growth hormone deficiency. By distribution channel, it is segmented by hospital pharmacies, clinics, retail pharmacies and online pharmacies.

The hormone replacement therapy market is assessed across key regions such as North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Middle East and Africa (MEA) and Japan.

Additional Questions Answered

Apart from key findings mentioned above, the hormone replacement therapy market report also answers additional questions such as:

Research Methodology

The hormone replacement therapy market is drafted using a unique research methodology comprising of a combination of secondary and primary research methodologies. The data gleaned from primary and secondary research is assessed along with information from external sources. All the statistics are compiled using triangulation method to gain highly accurate projections on hormone replacement therapy market.

Request methodology on hormone replacement therapy market report.

The growth projection of each of these segments and sub-segments is accurately tracked in the report along with east-to-understand graphs and tables. Further, the market share, size, value, and Y-o-Y growth of the Hormone Replacement Therapy market segments are included in the report.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=2224

Essential Takeaways from the Hormone Replacement Therapy Market Report

Important queries related to the Hormone Replacement Therapy market addressed in the report:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=2224

Why Choose Fact.MR

Read the original:
The Economic Impact of Coronavirus on Hormone Replacement Therapy Market: Business Opportunities, Current Trends and Industry Analysis by 2018 to 2028...

One year in, leaders of a student group dedicated to community support for transgender and nonbinary students hosted almost a dozen events in collaboration with multicultural groups on campus.

Transgender and Non-binary Students of GW, a student organization formed last April as a supportive space for trans and nonbinary students, collaborated with more than 10 other organizations to educate students on issues important to the community like hormone replacement therapy. Executive board members said they plan to build on their first years efforts by keeping all of their events annual and expanding this years Transgender Awareness Week into a two-week LGBTQ celebration.

Junior Aedy Miller, the organizations current director of marketing and public relations and president-elect, said TNBS members were key leaders in facilitating social and educational events for Transgender Awareness Week in mid-November. Miller said the group planned educational and speaker events aimed at creating an inclusionary space for students of all identities, like a workshop with Students Against Sexual Assault about sexual assault and survivorship in the trans community.

Trans Awareness Week this year encompassed 15 events intended to empower transgender and nonbinary students and educate students about the community and issues affecting it. Student leaders said the weeks events, like a spoken word mic night celebrating trans artists, will happen again at Septembers LGBTQ celebration, which will also feature a mini-Pride event after Junes Pride festival was canceled.

The way that we sought to build community was by thinking about those who werent in the rooms when we were planning meetings, Miller said. Always thinking about who can we work with too, like different organizations, different University departments, who can be worked with to create a welcoming and affirming space for students of all identities.

Miller said the organization expanded its outreach into the D.C. community during Transgender Awareness week through a sticker fundraiser with the Organization of Latino American Students, which raised more than $700 for Casa Ruby the only D.C. organization providing direct services, like housing, for low- or no-income queer individuals.

The organization was founded to create a space dedicated specifically for trans and nonbinary students with a dual focus on empowering the community on campus, and also working in the queer community in D.C and not just being a social organization, but also an advocacy organization, they said.

Miller said the organization had planned a postcard campaign directed at state legislatures enacting legislation blocking transgender youth from accessing hormones or participating in sports for International Transgender Day of Visibility on March 31 before students were sent home for the semester because of the COVID-19 outbreak.

After the event was canceled amid the pandemic, TNBS members decided to use Discord, a virtual chat website similar to GroupMe, to allow students to continue communicating with each other and to offer support to each other after moving back home.

Within the community there are some folks who just dont even have a home to go back to, Miller said. On the flip side, if folks have a place to go back to, people either have to go back in the closet, are put into toxic or even like emotionally abusive situations where theyre constantly misgendered or dont feel affirmed in their home and just not safe in their home.

Harvey Tate, the groups incoming vice president, said student leaders partnered with the Multicultural Student Services Centers LGBTQIA Resource Center to augment resources available to students, like chest binders for students transitioning, as part of their goal to advocate for greater representation of trans and nonbinary students.

Tate said members have also met with Student Association and housing officials to discuss University policies about changing ones name and about housing that does not represent trans and nonbinary students. He said the housing department currently assigns students rooms based on sex instead of gender, creating problematic situations for students who identify as gender-neutral or transgender who are then forced to chose a gender or are stuck in potentially harmful roommate situations.

Id rather fix the system than keep trying to Band-Aid patch it, Tate said. So the end goal is to fix the system. But thats a long-term goal that we cant necessarily get done in our first year, because we have to build those avenues of trust and work toward them.

Tate said the organization partnered with the Division for Student Affairs in the spring to run two Engagement in Leadership Seminars, sessions all student organizations are required to attend aimed at advancing student leadership. He said the sessions walked students through common misconceptions on transitioning and answered questions students may otherwise have been uncomfortable asking outside of the workshop.

A part of our goal as an organization is to educate as well as advocate, so the ELS sessions were an important part of that, Tate said.

Freshman Sophia Packer, TNBSs treasurer, said the organization earned an Excellence in Diversity award in April from DSA for demonstrating a significant commitment to diversity and inclusive excellence throughout the year. Packer said the organization has worked to include students of varying perspectives in events held throughout the year, like Transgiving, to build an inclusive space on campus.

It was really a way to recognize how a lot of us dont necessarily have the best home lives and a place for essentially a found family to come together and eat this delicious, enormous meal and just spend time feeling safe and comfortable, Packer said.

The rest is here:
Student group works to improve trans, nonbinary inclusion - GW Hatchet

Heres recently issued report on the Global Hormone Replacement Therapy (HRT) Market that allows you to offer a brief analysis of the market size, demand, supply chain, distribution channels, futuristic trends, market growth elements and so on. It offers a comprehensive analysis of assorted business aspects like global Hormone Replacement Therapy (HRT) market trends, recent technological advancements, market shares, size and new innovations. What is more, this analytical knowledge has been compiled through knowledge searching techniques like primary and secondary analysis for Hormone Replacement Therapy (HRT) industry. Moreover, an professional team of researchers throws lightweight on numerous static additionally as dynamic aspects of the worldwide Hormone Replacement Therapy (HRT) market.

Obtain sample copy of Hormone Replacement Therapy (HRT) market report: https://calibreresearch.com/report/global-hormone-replacement-therapy-hrt-market-4928#request-sample

Geographically, the worldwide Hormone Replacement Therapy (HRT) market has been analyzed in numerous regions like North America, geographical region, geographical region, Asia-Pacific, Africa, Europe and Asian nation. The worldwide Hormone Replacement Therapy (HRT) market region is dominating this market among the forthcoming future. Worldwide Hormone Replacement Therapy (HRT) market is that the skilled and correct study of assorted business views like key players, key geographies, divers, restraints, opportunities and challenges. This global analysis report has been mass on the concept of assorted market segments and sub-segments associated with the worldwide market.

Global Hormone Replacement Therapy (HRT) market competition by prime manufacturers, with Hormone Replacement Therapy (HRT) sales volume, value (USD/Unit), revenue (Million USD) and market share for each manufacturer. The report provides an in-depth analysis of the worldwide Hormone Replacement Therapy (HRT) Market progressing to cut back time to plug for products and services, cut back operational value, improve accuracy and operational performance. Besides this, the report elaborates crucial aspects such as fresh product establishment, greater expenditure in R&D and increasing demand in the manufacturing differentiable growth opportunities in the Hormone Replacement Therapy (HRT) Market globally.

Checkout Inquiry For Buying or Customization of Hormone Replacement Therapy (HRT) Market Report: https://calibreresearch.com/report/global-hormone-replacement-therapy-hrt-market-4928#inquiry-for-buying

The complete profile of the manufacturers are mentioned. And so the capability, production, price, revenue, cost, gross, margin of profit, sales volume, sales revenue, consumption, rate of growth, import and export, future strategies and therefore the technological developments that they are creating are also enclosed among the report. The historical knowledge and forecast knowledge from 2020 to 2026.

Leading companies reviewed in the Hormone Replacement Therapy (HRT) report are:

Abbott LaboratoriesNovartisPfizerMylan LaboratoriesMerck& Co.AmgenNovo NordiskBayerEli LilyWyethGenentech

The Hormone Replacement Therapy (HRT) Market report is segmented into following categories:

The product segment of the report offers product market information such as demand, supply and market value of the product.

The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.The Hormone Replacement Therapy (HRT) market report is segmented into Type by following categories;OralParenteralTransdermalOthers

The Hormone Replacement Therapy (HRT) market report is segmented into Application by following categories;MenopauseHypothyroidismMale HypogonadismGrowth Hormone DeficiencyOthers

Checkout FREE Report Sample of Hormone Replacement Therapy (HRT) Market Report for Better Understanding: https://calibreresearch.com/report/global-hormone-replacement-therapy-hrt-market-4928#request-sample

The report provides substantial knowledge relating to the market share that every one in every of these firms presently garner across this business, in tandem with the market share that they are expected to amass by the highest of the forecast period. Also, the report elaborates on details regarding the products manufactured by every of these companies, that may facilitate new entrants and outstanding stakeholders work on their competition and strategy portfolios. To not mention, their decision-making method is vulnerable to get easier on account of the actual fact that the Hormone Replacement Therapy (HRT) System market report additionally enumerates a gist of the products value trends and so the profit margins of each firm among the industry.

This will enable the readers to focus on Hormone Replacement Therapy (HRT) market product specifications, current competitive manufacturers in Hormone Replacement Therapy (HRT) market and also the market revenue with gain. Worldwide Industry Analyze Hormone Replacement Therapy (HRT) Market by competitive manufacturers, regions and applications of Hormone Replacement Therapy (HRT) market, forecast up to 2026. This report analyses the scope of Hormone Replacement Therapy (HRT) market. This will be achieved by Hormone Replacement Therapy (HRT) previous historical information, analysing qualitative insights info, demonstrable projections regarding global Hormone Replacement Therapy (HRT) market size.

Read this article:
Impact of COVID-19 Hormone Replacement Therapy (HRT) Market Industry Survey 2020-2026 Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories - NJ...

Targeting Q3 2020 initiation of an adaptive Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients, following IND submission and clearance

Acer to host conference call and webcast on Monday, May 11 at 5:30 pm Eastern Time

NEWTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), one of the National Institutes of Health (NIH), to develop emetine hydrochloride as a potential treatment for patients with COVID-19, the disease caused by infection with the SARS-CoV-2 virus. Under the terms of the agreement, Acer and NCATS will collaborate to accelerate the clinical development of emetine, a broad-acting and potent antiviral according to various preclinical and clinical studies.

Acer is in ongoing discussion with the Division of Antivirals (DAV) at the FDA after receiving its initial written responses to the Companys pre-Investigational New Drug (pre-IND) package. Acer is working toward an IND submission in mid-2020 and targeting clinical trial initiation in the third quarter of 2020, subject to additional capital. The Company has proposed an adaptive design Phase 2/3 randomized, blinded, placebo-controlled multi-center trial to evaluate the safety and antiviral activity of emetine in high-risk, symptomatic adult patients with confirmed COVID-19 infection not requiring hospitalization. The trial objectives as planned are to determine the safety and efficacy of emetine via clinical status at a specific timepoint in addition to disease resolution.

Acer is concurrently pursuing several financing options, including federally-funded research and grants, to support emetine development. For example, the Biomedical Advanced Research and Development Authority (BARDA) invited the Company to present the emetine development program at the BARDA CoronaWatch meeting on May 7, 2020. BARDA CoronaWatch is a funding program providing government support for selected coronavirus projects. While Acer plans to advance emetine through IND submission, initiation of the clinical trial of emetine is contingent on the timely availability of additional capital to fund this program.

Emetine will be delivered as a sterile subcutaneous injection. Acer will oversee the contract synthesis and manufacturing of emetine for clinical development and potential commercialization.

We are very pleased to be selected by NCATS and look forward to collaborating on the development of emetine, a broad-acting and potent antiviral identified by NCATS as their best preclinical opportunity for further clinical development for the treatment of COVID-19, said Chris Schelling, CEO and Founder of Acer. With a collaboration agreement in place, ongoing discussions with the FDA toward IND submission, and several potentially non-dilutive funding sources being pursued, we believe we are well-positioned to advance the clinical development of emetine.

Conference Call and Webcast DetailsInterested parties can access the live call and webcast on Monday, May 11, 2020, at 5:30 pm Eastern Time (2:30 pm Pacific Time) from the Investors section of Acers website or directly athttp://public.viavid.com/index.php?id=139741. Participants can also access the call by dialing 800-458-4148 (US Toll Free) or 1-720-543-0206 (International Toll Number) and providing the Conference ID 8855853. A replay of the call will also be available under the Investors section of Acers website.

About Emetine HydrochlorideAcer and NCATS are working together to develop emetine for the treatment of patients with COVID-19, the disease caused by the SARS-CoV-2 virus. Emetine is an active pharmaceutical ingredient of syrup of ipecac, given orally to induce emesis, and has also been formulated as an injectable to treat thousands of individuals with amebiasis. Several independent in vitro studies have demonstrated nanomolar potency against both DNA and RNA-replicating viruses, including Zika virus, Ebola virus1, Rabies Lyssavirus, human cytomegalovirus, human immunodeficiency virus 1, influenza A virus, Rift Valley fever virus, echovirus 1, human metapneumovirus, and herpes simplex virus type 22. Clinically, emetine has been used to treat approximately 700 patients (including pediatrics) with viral hepatitis3 and varicella-zoster virus4. Additionally, emetine is a potent inhibitor of multiple genetically-distinct coronaviruses and demonstrated in vitro the strongest anti-coronavirus activity in one study that screened and identified approved compounds with broad-spectrum efficacy against the replication of four coronaviruses5 and specifically against SARS-CoV-2.6

Acer intends to initially seek FDA approval to market emetine in the U.S. using a regulatory pathway established under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act that allows applicants to rely at least in part on third party data for approval. The Company intends to rely in part on the existing preclinical and clinical safety data for emetine, while supplementing with the COVID-19 safety and efficacy data to be generated in the Phase 2/3 trial as well as chemistry, manufacturing and controls information. If the Phase 2/3 trial is completed successfully, following IND submission and clearance, Acer anticipates submitting to the FDA the 505(b)(2) NDA for emetine for the treatment of COVID-19. The potential initiation of the Phase 2/3 trial, its conduct and completion and NDA submission are subject to the Companys ability to generate sufficient capital resources to fund this program. Emetine is an investigational drug for COVID-19 and is not currently FDA approved for any indication.

About the National Center for Advancing Translational SciencesThe National Center for Advancing Translational Sciences (NCATS) one of 27 Institutes and Centers at the National Institutes of Health (NIH) was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster. Its focus is to advance the science of translation, which is the process of turning observations into interventions to improve health. NCATS collaborates with researchers, the public and other stakeholder groups to design new approaches and technologies that ultimately will deliver more treatments to more people more quickly.

About Acer Therapeutics Inc.Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acers pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS) where Hormone Replacement Therapy (HRT) is likely contraindicated. Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit http://www.acertx.com.

References

Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, timelines, future financial position, future revenues, projected expenses, regulatory submissions, actions or approvals, cash position, liquidity, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential for our product candidates to safely and effectively treat diseases and to be approved for marketing; the commercial or market opportunity of any of our product candidates in any target indication and any territory; our ability to secure the additional capital necessary to fund the emetine program; the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials and regulatory submissions; the ability to protect our intellectual property rights; our strategy and business focus; and the development, expected timeline and commercial potential of any of our product candidates. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on managements current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet our business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by our intellectual property, the substantial costs and diversion of managements attention and resources which could result from pending securities litigation, risks related to the drug development and the regulatory approval process, including the timing and requirements of regulatory actions, and the impact of competitive products and technological changes. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K. You may access these documents for no charge at http://www.sec.gov.

Investor Contact:Hans VitzthumLifeSci AdvisorsPh: 617-430-7578hans@lifesciadvisors.com

Jim DeNikeAcer Therapeutics Inc.Ph: 844-902-6100jdenike@acertx.com

Here is the original post:
Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One...

Beauty is not just skin deep. Your hormones play a big role in your external beauty too. Any abnormalities in your hormones can wreak havoc on your skin health. There come many phases in a womans life when there may be disruptions in hormones. Moreover, many diseases like thyroid, which are more common in women, also cause these disruptions. But there is nothing to worry about here. You can easily deal with this if you make a few changes in your life. You dont have to undergo expensive salon treatments or therapies, nor do you have to go in for any medical treatment. But before attempting to handle these conditions on your own, you need to know what exactly hormones are. These are nothing but chemical messengers secreted by glands. It facilitates many activities in your body including growth and development, metabolism, mood and sexual function. Some of the common hormones in your body are thyroid, cortisol, insulin, estrogen, testosterone and progesterone. Also Read - Skincare tips: Why you should exfoliate your skin and how to do it at home

According to researchers at UT Dell Medical School and Ascension Seton in Austin, Texas, your hormones dont just control how you feel. They can have an impact on the health of your skin, too. Some hormonal disorders manifest themselves in the skin and hair too. If your body is deficient in thyroid hormone, a condition called hypothyroidism, you may experience dry skin among other things. On the other hand, over production of the androgen hormone can make your skin excessively oily. During menopause, when a womans estrogen levels go down, she may experience dry and itchy skin. These are just a few examples. Also Read - Eat your sunscreen to protect your skin from the inside out: 6 foods that have SPF qualities

Let us take a look at how hormones can affect your skin at different stages of your life and how to deal with it. Also Read - Five worst enemies of your skin and how to combat them

This is the time when your body increases the production of both estrogen and testosterone. This results in excess sebum production and this makes your skin very oily. Outbreak of hormonal acne is very common during this stage in life.

How to handle this: Wash your face frequently and avoid using heavy facial creams. If the outbreak is too severe, consult a doctor. There are many topical ointments that can help. If you are a woman, your doctor may sometimes recommend hormonal birth control pills. You can also try out some home remedies to get rid of this problem. Apply sandalwood and turmeric paste or wash your face with lemon water. This will help to some extent.

When you are pregnant, your body produces excess estrogen. This can cause your skin to change to a darker tone. Some women also experience discolouration on their facial skin. This is called melasma.

How to handle this: Avoid sun exposure. You skin becomes extremely sensitive during this time. If you have to go out during the day, use a good sunscreen after consulting your doctor. Maintain a daily skin care ritual and stay hydrated. Follow a healthy diet that includes a lot of fresh fruits and vegetables. Drink enough water and do some moderate exercise. This will make your skin radiant.

This is the phase of life where your body stops the production of estrogen. As a result, your skin loses its elasticity and you start noticing fine lines and wrinkles. You may also experience dry skin around this time.

How to handle this: If you consult your doctor, he may recommend hormone replacement therapy (HRT) or prescribe bioidentical hormones (BHT). But you can also handle this on your own by eating properly and keeping your skin moisturized and hydrated. Sleep well at night and avoid stress for a radiant skin. Avoid alcohol and smoking and exercise. All this will make your skin glow despite your hormones going haywire.

Published : May 12, 2020 5:14 pm

Go here to read the rest:
Fluctuating hormones can wreak havoc on your skin health: Know how to deal with it - TheHealthSite

SAN DIEGO AND DURHAM, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- Dar Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, today announced that the companies have signed a partnership agreement under which Health Decisions will exclusively provide CRO services within the United States to support the clinical development of Dar’s innovative pipeline of novel programs designed specifically to address persistent unmet needs in the areas of contraception, fertility, and broader gynecological disorders. Dar and Health Decisions have successfully worked together on prior Dar clinical studies, including the post-coital test clinical study of Ovaprene®. The partnership agreement provides for dedicated resources and new pricing structures, which, together with Health Decisions’ expertise, site network and relationships with key opinion leaders and investigators, are expected to accelerate clinical development of key programs in a capital-efficient manner.

One of the clear goals of this strategic partnership is to leverage Health Decisions’ expertise in clinical development of women’s health products,” said Sabrina Martucci Johnson, President & CEO of Dar Bioscience. Health Decisions is the Statistical and Clinical Coordinating Center for the Contraceptive Clinical Trials Network of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a unit of the National Institutes of Health (NIH), and in this capacity they have conducted more than 40 clinical trials in contraception, as well as a number of other therapeutic areas aligned with Dar’s broad and diverse portfolio of women’s health programs. We believe their deep domain expertise coupled with their clinical and technical acumen will enable us to accelerate clinical development activities across our portfolio. Further, we believe the pricing structure under the partnership agreement will result in cost savings in our clinical development expenditures.”

Under the terms of the agreement, Health Decisions will be Dar’s exclusive provider of CRO services within the United States for all of Dare’s reproductive health assets for an initial three-year period, provided that Health Decisions has the expertise, resources and availability to perform the clinical research services that Dar requires. This includes the assets that Dar has or may have in development for pregnancy and delivery, contraception, infertility, polycystic ovarian syndrome and endometriosis during that period. In exchange for CRO exclusivity, Health Decisions will provide a core team of personnel dedicated to supporting all of Dar’s development programs covered by the agreement, including Dar’s pivotal clinical study of Ovaprene®, a hormone-free, monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer, and the planned DARE-BV1 Phase 3 study in bacterial vaginosis, with topline data expected in 2020.

It is an honor for Health Decisions to be selected as a partner by Dar,” said Dr. Patrick Phillips, Chief Executive Officer of Health Decisions. Our like-minded commitment to women’s health has allowed us to foster an already highly productive relationship, and we look forward to supporting the acceleration of Dar’s unique pipeline with even greater efficiency moving forward.”

About Dar Bioscience

Dar Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Dar’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Dar’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit http://www.darebioscience.com.

Dar may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Dar posts on its investor relations website or through social media channels may be deemed to be material information. Dar encourages investors, the media, and others interested in the company to review the information Dar posts on its investor relations website (https://darebioscience.gcs-web.com/) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Dar’s website mentioned above.

About Health Decisions

Health Decisions is a full-service contract research organization offering therapeutic, operational and regulatory excellence for the clinical development of drugs, medical devices and combination drug/devices in all areas of women’s health as well as the development of diagnostics. Based on experience and investigator relationships developed over the past 30 years, Health Decisions successfully addresses the challenges of developing assets in areas including reproductive and sexual health, menopause, pain management, osteoporosis, osteoarthritis, reproductive psychiatry, and gynecologic oncology. In addition, Health Decisions conducts studies of diagnostics in women’s health, oncology and infectious disease. Health Decisions’ headquarters is in Durham, North Carolina.

For more information, visit http://www.healthdec.com.

Forward-Looking Statements

Dar cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe,” may,” will,” estimate,” continue,” anticipate,” design,” intend,” expect,” could,” plan,” potential,” predict,” seek,” should,” would,” contemplate,” project,” target,” tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Dar’s expectations that its partnership agreement with Health Decisions will accelerate clinical development of its programs and result in cost-savings and the anticipated timing for topline data from Dar’s planned Phase 3 study of DARE-BV1 for the treatment of bacterial vaginosis. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risk and uncertainties related to: the effects of the COVID-19 pandemic on Dar’s operations, financial results and condition, and ability to achieve current plans and objectives; the effects of the COVID-19 pandemic on the ability of third parties on which Dar relies to assist in the conduct of its business, including its clinical trials, to fulfill their contractual obligations to Dar; Dar’s ability to raise additional capital when and as needed to advance its product candidates and continue as a going concern; Dar’s ability to develop, obtain regulatory approval for, and commercialize its product candidates; the failure or delay in starting, conducting and completing clinical trials or obtaining FDA or foreign regulatory approval for Dar’s product candidates in a timely manner; Dar’s ability to conduct and design successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical studies of that candidate; Dar’s ability to retain its licensed rights to develop and commercialize a product candidate; Dar’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product candidates; developments by Dar’s competitors that make its product candidates less competitive or obsolete; Dar’s dependence on third parties to conduct clinical trials and manufacture clinical trial material; Dar’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Dar’s product candidates which could expose its products to competition from other formulations using the same active ingredients; the risk of failure associated with product candidates in preclinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund; and disputes or other developments concerning Dar’s intellectual property rights. Dar’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Dar’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts:

Investors on behalf of Dar Bioscience, Inc.: Lee Roth Burns McClellan 1.212.213.0006 lroth@burnsmc.com

Media on behalf of Dar Bioscience, Inc.: Jake Robison Canale Communications 1.619.849.5383 jake@canalecomm.com

Media on behalf of Health Decisions, Inc.: Danielle Kroft Health Decisions 1.919.967.1111 x139 dkroft@healthdec.com

View post:
Dar Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Dar's Novel Pipeline of Women's Health Programs |...

NEW YORK, May 12, 2020 /PRNewswire/ --Hospital for Special Surgery (HSS) in New York City is currently studying the effect of blood flow restriction (BFR) therapy following Achilles tendon rupture and repair. The study is made possible in part by an $18,000 grant from the American Orthopaedic Foot & Ankle Society's Research Committee to principal investigator Mark C. Drakos, MD, an orthopedic surgeon at HSS, and his research team.

"Normally, patients undergoing Achilles surgery take a year to return to sport. We are hoping to cut that down by at least 30% and potentially make patients stronger as well," said Dr. Drakos. "Blood flow restriction therapy is an accelerated rehabilitation protocol. The therapy essentially creates an environment in the muscle where it makes the muscle work as hard as if it is lifting heavy weights when it is lifting smaller weights. Cutting off the blood flow tricks the muscle into working harder than it actually would be doing."

Achilles rupture often presents a difficult recovery for patients, who commonly suffer a 10% to 30% strength reduction in the affected leg up to one year postoperatively. "Achilles rupture is really common in people who do explosion types of sports such as basketball, football and soccer, any sport where you are doing a lot of cutting," said Dr. Drakos. "With regards to Achilles injuries, once you put the tendon back together, you can't stress it right away or that will pull the repair apart. Regular rehabilitation can't start until six weeks after surgery. Unfortunately, this can lead to significant muscle atrophy, which can take months to recover. Blood flow restriction therapy allows us to work the muscle right away, so it doesn't atrophy and shrink. It safely allows the muscle to see some loading and develop more muscle, so that it can actually start to recover while the tendon is not completely healed yet."

Blood flow restriction training is believed to bring about strengthening and hypertrophic (muscle building) effects similar to those achieved through completion of high-intensity training, but at significantly lower load intensities. In healthy elderly populations, studies have shown increases in muscle strength when using BFR therapy in combination with low-intensity exercises. Research on the usefulness of BFR therapy with lower-intensity exercises in postoperative populations is in the early stages, with some studies showing benefit for individuals undergoing anterior cruciate ligament (ACL) reconstruction. Specifically, BRT therapy in the early postoperative period of ACL reconstruction has been shown to decrease atrophy and increase strength in the quadricep, when compared with immobilization and a physical therapy protocol. A study investigating the use of BFR therapy following knee arthroscopy also demonstrated a greater increase in strength and thigh girth when compared to a control group. To date, the use of BFR therapy for Achilles rupture rehabilitation has not yet been studied in a quantitative and prospective fashion.

The new BFR study is recruiting 60 patients, all of whom will have Achilles tendon repair surgery by Dr. Drakos. Half of the patients will receive BFR therapy and half will receive standard rehabilitation therapy involving range of motion exercises at two weeks and muscle-building exercises at six weeks. In the BFR therapy group, a blood pressure cuff will be placed on the thigh of a patient while they start their rehab on post-op day two with exercises such as ankle range of motion, leg extensions, leg curls and leg press.

"We think that an ounce of prevention is worth a ton of cure," said Dr. Drakos. "If we can prevent the muscles from atrophying, which they would normally do after a surgery, and we can prevent that from happening in a safe and structured fashion, then this will help our patients get better faster. Usually, you can't start rehab until six weeks after surgery."

The cuff allows some blood flow into the muscle, but prevents much of the venous blood flow return, so the muscle engorges with blood. "Ultimately, what this does is that a lot of the metabolites that encourage growth, including growth hormone, end up being sent to the areas to encourage hypertrophy," said Dr. Drakos. "Normally, if you want to make your muscles larger, you have to work with heavy weights. If you work out with light weights, you usually get toned, but you usually don't get large increases in muscle mass. What blood flow restriction therapy allows you to do is use low weight but still get the same effect you would with large weights."

A Cybex testing machine will objectively quantify changes in muscle strength, measuring how quickly the muscles fatigue and measuring their peak strength. All BFR therapy sessions will be supervised by a physical therapist certified to administer the therapy to ensure safety. To date no significant negative side effects have been observed, however, this technique needs to be further researched to evaluate this. To minimize risks to patients and maximize safety, the BFR device used for therapy individualizes the tourniquet pressure for each patient to be between 60% and 80% of their limb occlusion pressure. Study criteria include active patients who are undergoing Achilles surgery for an acute tear without significant medical co-morbidities.

Other members of the research team include Stephanie Eble, BA, Oliver Hansen, BA, and Andrea Papson, DPT.

About HSS

HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the tenth consecutive year), No. 3 in rheumatology by U.S. News & World Report (2019-2020), and named a leader in pediatric orthopedics by U.S. News & World Report "Best Children's Hospitals" list (2019-2020). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 130 countries. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.www.hss.edu.

SOURCE Hospital for Special Surgery

http://www.hss.edu

Link:
HSS Awarded Grant for Trial of Blood Flow Restriction Therapy After Achilles Tendon Repair - PRNewswire

Dear reader, here you will find three stories of transgender and genderqueer students from NYU. All of them embarked on separate journeys of self-discovery and self-acceptance once they found themselves in college. They faced various challenges along the way and preserved in their goal of living at their most authentic selves.

For August, attending NYU was a dream come true.

They had come out as transgender at the beginning of their high school career. NYUs location in Greenwich Village, a hub for the LGBTQ+ movement and home to the Stonewall Inn, presented an exciting experience suited for August.

New York, and NYU by proxy, associates with a queer-friendly climate. At the university, such an environment was created by the clubs and alliances run by and for LGBTQ+ students and staff members from all across the spectrum. Theres also a graduation ceremony that celebrates queer students and The Gender and Sexuality Team at the Student Health Center, helping transgender and gender-nonconforming individuals transition, explore their identities in a safer environment and live as their authentic selves.

Advertisement

August, now a Steinhardt graduate, turned their tassel at Yankee Stadium last May. They had spent their last four years at NYU coming into themselves as an active member of NYUs LQBTQ+ community and the president of T-Party, a safe space on campus for TGNC individuals.

August saw NYU as their excuse to get as far as physically possible from LA, where they were stuck in an inhibiting home environment with their father, an avid conservative, and their mother, misinformed on LGBTQ+ issues. But, in preparation for the cross-country move, August had a difficult promise to keep.

[My parents] said I was going to NYU if I dont medically transition, August said. My tuition was on the line. I agreed. It was either go to my dream school or not go to my dream school.

With this, August left for New York. Regardless, they were excited for a change in the environment. But they never really intended on keeping their promise to their parents. They spent their first two years getting acclimated to college life, but the promise they made weighed heavy on their mind.

My dysphoria was getting worse, and I was going into such deep depression watching all of my friends transition, August said. Just knowing that there was this thing I could be doing for myself, but there was this arbitrary reason that I couldnt.

Junior year came and August pushed their fear of backlash from their family aside, concerned more with their own happiness and decided to start medically transitioning.

In preparation to medically transition, many transgender individuals decide to take either testosterone or estrogen to develop masculine or feminine traits, respectively, a procedure known as Hormone Replacement Therapy. After completing a blood test at the Student Health Center, it was determined that they were healthy enough to get on testosterone. Hormones can be taken in a variety of ways, including applying a hormone-induced gel on your shoulder or forearm and receiving intramuscular injections. August started taking hormones at the beginning of their junior year in the form of AndroGel gel pumps.

After Augusts parents found out through an insurance company notification, they took August off their insurance plan and presented an ultimatum: If August wanted to stay at NYU, they had to stop taking hormones. August refused and, eventually, their parents agreed to keep paying their tuition if they saw a therapist in the city.

After being on testosterone for nearly two years, August decided to get top surgery, a common type of gender-confirmation surgery which involves breast removal in order to create a masculine chest. With no medical insurance from their parents, August needed alternative payment methods to cover the surgery.Luckily for them, NYUs Consolidated Health Plan partially covered it. The rest came from Augusts GoFundMe, Augusts Transition Fund. Many things changed for August since their surgery, even their relationship with their parents improved.

Things are good between me and my parents right now, I think, August said with a smile. A lot of their transphobia is seeded in fear that me being trans will hinder me in some way. Its up to them to do the work on other people instead of working on me. Working on other people being comfortable with me.

With a coffee cup in her hand, Remy Elliott looks serene. Her saturated pink lipstick seems to be exactly the right shade to match her pale purple blouse. Her mouth forms a slight smile. When she talks, her voice is soft.

Steinhardt Masters in Childhood Education student Elliott publicly came out as transgender during her senior year in college. Elliott began by coming out to her close friends only. Feeling their acceptance of her authentic identity, she made an announcement on Facebook for International Womens Day in March of 2019, hoping to reach her hometown friends, acquaintances and distant family alike.

After years and years of careful thought and reflection, Im so happy to finally announce that I am transgender! Elliotts post reads. From here on out, Ill be living my life as the woman that Ive always been! Id like to be called by my real name, Remy, and not my deadname

Coming out later in her college career bore a lot of challenges for Elliott, externally and internally. While she began mentioning her struggle with her then-cis gender identity to friends around her sophomore year, coming out more publicly took time and seeking for validation from within. Elliott was worried she wasnt transgender enough.

For a long time, I was under the impression that I was trans but will never do anything about it, Elliott said. My dysphoria wasnt so bad that I felt like I was living a lie constantly. I could kind of make it through as a man.

But the pressure grew as the end of college approached. As a senior majoring in education, she had to have a teaching placement and was assigned to teach in a New York primary school last January.

Wishing to enter her new workplace as her real self, Elliott pushed herself to make a switch from masculine to feminine pronouns.

Contributing to the difficulties was the mismatch in the way Elliott felt and the way she was perceived from the outside. For many transgender individuals, theres a distinction between coming out and socially transitioning. For some, the two go hand-in-hand. For others, the choice to do one or the other can be more nuanced, involving difficult financial decisions, possible medical roadblocks including health conditions and considerations, lack of appropriate insurance coverage or potential judgement of those closest to the person. While social transitioning usually involves a name change, after which ones birth name becomes their deadname, and a pronouns switch, medical transitioning involves a multitude of procedures, including hormone replacement therapy and top or bottom surgeries.

Even with her determination to finally come out as a trans-woman, she found it difficult to navigate the resistance in her immediate community. The closest of her friends made the switch with no issues but the majority of the community around her struggled with misgendering and deadnaming Elliott.

Once I started going full-time [as a female] it got easier for people to come to terms with, Elliott said. When I was fluid, people had a harder time wrapping their heads around it.

After coming out, I didnt start transitioning immediately, Elliott said. I kept wearing masculine clothes and went by my deadname for a while.

Later in her senior year, Elliott began experimenting with her appearance, practicing different makeup techniques she enjoyed and building a more feminine wardrobe, discovering what clothes she felt most comfortable in. Towards the end of her senior year, Elliott chose to begin HRT and started taking estrogen with the intention of feminizing her appearance further. As an NYU student, she had Comprehensive Healthcare Plan insurance through Wellfleet, which covered the cost of her HRT.

For the Transgender Day of Visibility celebrated on March 31, Somaya Gupta posted a picture of themselves ready to shave, with the shaving cream on their face and a razor in their hand.

I have a distinct memory of being a kid and watching my dad shave his face and thinking that looks so fun, I wish I could do that, Gupta wrote in the caption. But growing up as a brown girl, I quickly learned that shaving my face was not acceptable One incredible lesson Ive learned through accepting my transness is that the instincts you had as a child were usually right

Gupta, who is graduating from Steinhardt this year, identifies as genderqueer and uses any pronouns. Despite being a senior, Gupta finds themselves in the process of still figuring out the labels they feel most comfortable with and where they fall on the gender spectrum.

At some point during their first year, Gupta and their then-roommate went to a friends dorm. The friend identifies as non-binary. On their way back, Guptas roommate asked what non-binary meant and Gupta explained, ultimately wondering how people ever realized their genderqueerness.

Does anyone ever feel like their gender? Gupta asked. You just say youre a girl because you were told that, right? But she was like no, you feel like a girl and so panic ensued.

In their sophomore year, Gupta, still silently questioning themselves but leaving the thoughts about their gender identity on the backburner, joined Shades, seeking a community of LGBTQ+ people of color who could relate to and understand their intersectional experience.

Throughout their time at NYU, theyve been involved with LGBTQ+ advocacy as the president of Shades LGBTQ+ Centers club for Black queer people and queer people of color and serves as a campus ambassador for GLAAD. While advocating for others, Gupta found themselves on their own journey of self-discovery and self-acceptance.

By their junior year, they had a lot of transgender and genderqueer friends, to whom they related a lot. This allowed them to begin self-discovery without the fear of losing their loved ones.

Junior year, when I came back from winter break, we had our first Shades meeting, Gupta said. We all go around and say our names and pronouns. And I said to everyone, when I usually said she and her, Im not sure so Ill just go with any pronouns. After I said that, a couple of people were like woo, thats cool!

All of Guptas friends were very supportive when they came out to them. So was Guptas older sister, who helped Gupta educate their parents about genderqueer people to avoid possible misunderstandings for whenever Gupta might choose to share their identity with the rest of their family. When they did, their parents accepted their child.

We were on vacation, I knew they would be more relaxed, Gupta laughed. I was saying how in queer spaces it was very common for people to say their pronouns and my mom said well, what pronouns do you say? I [said] yeah, Im genderqueer, and my mom was like, wow, shocker! She knew it was coming.

As a process of their coming out, Gupta began more openly expressing their queerness on social media. They started experimenting with their appearance, cutting their hair because having long hair no longer felt as though it was them. As of late, they have begun posting pictures of the way they changed thanks to the workouts they have taken on to make their body suit their mind better. But medically transitioning by going on testosterone, even though desired, feels like a risk too high to take right now. Guptas a musician and their voice might change in unpredictable ways if they were to start HRT.

So Im taking more time to think about it, what dosage I would need and finding the right doctor for my situation and stuff, Gupta said. I would look forward to being more muscular, my hips being less prominent wider face and neck! I would look forward to mostly just people looking at me and not automatically assuming Im a girl.

For each of these students, their path to becoming and presenting as themselves has been a complex one, and each of them finds themselves at a different place in their journeys.

Right now Gupta is getting ready to graduate, eagerly looking at their future and preparing new music for release. Their single Do You Ever will be available for streaming on May 15. August is currently living in New York as an openly trans person with their dog, Frank. They have fully recovered from their top surgery and model for We Speak Models. Elliott is continuing her journey with NYU as a graduate student, preparing to become an educator and feeling happy to have CHP insurance covering estrogen, which she started last spring as a part of her medical transitioning path.

Just like their transitions, the lives of August, Elliott and Gupta go on.

Correction, May 8:The last name of an individual profiled was removed upon request after publication. This article has been updated to reflect this and WSN regrets any errors.

Email Anna-Dmitry Muratova at [emailprotected] A version of this article appears in the Friday, May 8, 2020, print edition. Read more from Washington Square News While You Were Here 2020.

Advertisement

See the rest here:
Coming to University and Into Their Own - NYU Washington Square News

Initial public offerings, or IPOs, usually garner lots of attention. And why not? Like sports teams jockeying for top prospects on draft day, investors line up to own a piece of the company as it commences trading. The company, its employees, and existing investors clamor to see whether the stock will jump or sink, adjusting their net worths accordingly.

IPOs carry tremendous amounts of risk, and trading publicly begins a new phase in the company's life. Drug development firms add in layers of additional risk -- clinical trial efficacy and safety risks, regulatory risk such as approval by the U.S. Food and Drug Administration (FDA), and reimbursement risk. Small drug developers endure twists, turns, setbacks, and reinventions along the road to hopefully achieving success. Investors in biotech companies aim to achieve outsized returns for assuming this multitude of risks.

Image source: Getty Images.

Virtually all biotech IPOs occur while the company is still in the research and development stage. The companies go public to raise money to fund that research. Amarin (NASDAQ:AMRN) is no exception. After completing its IPO in 1993, the Amarin that investors know today is unrecognizable as the company that went public in the early 1990s.

Known as Ethical Holdings, the company started as a transdermal patch drug delivery outfit that licensed its technology to other companies. Internally, it had focused on using the patch to administer hormone replacement therapy. In 1999, Amarin sold the patch technology and acquired rights to two drugs, one marketed and one in development, for treating symptoms of Parkinson's disease. The company changed its name to Amarin with this shift in business.

With a new therapeutic focus, Amarin set off to expand its pipeline. In 2000, the company licensed a drug for Huntington's disease and other neurological conditions. This drug went on to be the main focus of the company until it failed in 2007 in two phase 3 clinical trials for the treatment of Huntington's disease. The drug performed no better than placebo against the primary and secondary endpoints. Of course, the stock dropped like a bag of bricks, losing around 75% of its value.

However, in 2004, Amarin made a savvy acquisition of private company Laxdale Limited, which gave it (among other assets) a novel lipid technology platform. This platform would eventually lead to Amarin's currently approved cardiovascular disease drug Vascepa.

Amarin's stock price today is intimately connected to the success of Vascepa, which is derived from fish oil. When the FDA approved an expanded indication for the drug last December, the stock rose. However, when a district court ruled one of Vascepa's patents invalid at the end of March, opening the way for generic competition, the stock tanked.

Investors in Amarin's IPO have little to show for themselves despite holding the stock for 27 years. According to data from YCharts, an initial $10,000 investment would be worth roughly $127 today. Ouch! That's a testament to the continuous need for capital and therefore dilution to shareholders that can happen in the long, arduous road to successfully developing a drug.

Don't get me wrong. Plenty of biotech investors have made money owning Amarin stock over the years. This is a lesson for buy-and-hold investors. As the business undergoes significant changes, as it did over the life of Amarin, investors must reassess their investment thesis and time horizon.

If investors had instead put $10,000 into the 1993 IPO for the tech company Intuit (NASDAQ:INTU), those investors would be sitting pretty. That investment would be worth approximately $1.13 million today.

Image Source: YCharts

This isn't to say tech IPOs are better than biotech ones. It simply illustrates that after 27 years of being public, companies can be deemed successful or not. Amarin has an approved drug on pace to generate hundreds of millions in revenues this year -- but the stock performance does not always correlate.

See the rest here:
If You Invested $10,000 in Amarin's IPO, This Is How Much Money You'd Have Now - The Motley Fool

Research report on global Hormone Replacement Therapy (HRT) Market 2020 with industry-primary research, secondary research, product research, size, trends, and Forecast.

The Hormone Replacement Therapy (HRT) report provides independent information about the Hormone Replacement Therapy (HRT) industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Hormone Replacement Therapy (HRT) Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Hormone Replacement Therapy (HRT) Market: Products in the Hormone Replacement Therapy (HRT) classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories, Merck & Co., Amgen, Novo Nordisk, Bayer, Eli Lily, Wyeth, Genentech

Table Of Content

Market Overview: Scope & Product Overview, Classification of Hormone Replacement Therapy (HRT) by Product Category (Market Size (Sales), Market Share Comparison by Type (Product Category)), Hormone Replacement Therapy (HRT) Market by Application/End Users (Sales (Volume) and Market Share Comparison by Application), Market by Region (Market Size (Value) Comparison by Region, Status and Prospect

Hormone Replacement Therapy (HRT) Market by Manufacturing Cost Analysis: Key Raw Materials Analysis, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials, Proportion of Manufacturing Cost Structure (Raw Materials, Labor Cost), Manufacturing Process Analysis

Hormone Replacement Therapy (HRT) Market Report Covers the Following Segments:

Segment by Type:

OralParenteralTransdermalOthers

Segment by Application:

MenopauseHypothyroidismMale HypogonadismGrowth Hormone DeficiencyOthers

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Key Benefits for Stakeholders

The study provides an in-depth analysis of the Hormone Replacement Therapy (HRT) market size along with the current trends and future estimations to elucidate the imminent investment pockets.

Information about key drivers, restraints, and opportunities and their impact analysis on the market size is provided.

Porters five forces analysis illustrates the potency of buyers and suppliers operating in the portable gaming industry.

The quantitative analysis of the Hormone Replacement Therapy (HRT) industry from 2020 to 2026 is provided to determine the Hormone Replacement Therapy (HRT) market potential.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

Market Research Bazaar

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

See the rest here:
Hormone Replacement Therapy (HRT) Market Set for Rapid Growth and Trend by 2025 Cole Reports - Cole of Duty